Floatz logo

Ispinesib

Splenic Marginal Zone Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Splenic Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BB
Zanubrutinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Ispinesib is also rated in:

breast cancerDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →